Non Driver NSCLC: The Immunotherapy Strategy

Luis E. Raez MD FACP FCCP
Chief Scientific Officer & Medical Director
Memorial Cancer Institute/Memorial Health Care System
Florida Cancer Center of Excellence
Research Professor I-Health Institute Florida Atlantic University
Past-President Florida Society of Clinical Oncology (FLASCO)

@LuisRaezMD

First Line Lung Cancer Therapy with no actionable genes

NSQCC:
- Carboplatin/Pemetrexed/Pembrolizumab [Keynote 189]
- Carboplatin/Paclitaxel/Bevacizumab/Atezolizumab [IMPOWER 150]

SQCC:
- Carboplatin/Paclitaxel or nab-paclitaxel/Pembrolizumab [Keynote 407]

NSQCC and SQCC:
- Cemiplimab/Chemotherapy [Empower Lung-3]
- Durvalumab +Tremelimumab/Chemotherapy [Poseidon 3]

**IO single Agent (NSQCC OR SQCC)**
- Pembrolizumab [Keynote 024 and 042]
- Atezolizumab [IMPOWER 110]
- Cemiplimab [Empower Lung-1]

Immunotherapy combinations:
- Ipilimumab and Nivolumab [Checkmate 227]
- Ipilimumab and Nivolumab plus 2 cycles of chemotherapy [Checkmate 9LA]

POSEIDON Study Design

Phase 3, global, randomized, open-label, multicenter study

- Stage IV NSCLC
- No *EGFR* or *ALK* alterations
- ECOG PS 0 or 1
- Treatment-naïve for metastatic disease

N=1013 (randomized)

R 1:1:1

Stratified by:
- PD-L1 expression (TC ≥50% vs <50%)
- Disease stage (IVA vs IVB)
- Histology

Durvalumab 1500 mg + CT* q3w (4 cycles)

Durvalumab 1500 mg q4w + pemetrexed† until PD

Durvalumab 1500 mg + tremelimumab 75 mg + CT* q3w (4 cycles)

Durvalumab 1500 mg q4w + tremelimumab 75 mg (week 16 only)‡ + pemetrexed† until PD

Platinum-based CT* q3w (up to 6 cycles)

Pemetrexed† until PD

Primary endpoints
- PFS by BICR (D+CT vs CT)
- OS (D+CT vs CT)

Key secondary endpoints
- PFS by BICR (D+T+CT vs CT)
- OS (D+T+CT vs CT)
- OS in patients with bTMB ≥20 mut/Mb (D+T+CT vs CT)

Additional secondary endpoints
- ORR, DoR, and BOR by BICR
- PFS at 12 months
- HRQoL
- Safety and tolerability

*CT options: gemcitabine + carboplatin/cisplatin (squamous), pemetrexed + carboplatin/cisplatin (non-squamous), or nab-paclitaxel + carboplatin (either histology); †Patients with non-squamous histology who initially received pemetrexed during first-line treatment only (if eligible); ‡Patients received an additional dose of tremelimumab post CT (5th dose)

BICR, blinded independent central review; BOR, best objective response; bTMB, blood tumor mutational burden; D, durvalumab; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; HRQoL, health-related quality of life; Mb, megabase; mut, mutations; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; q4w, every 4 weeks; T, tremelimumab; TC, tumor cell

Durvalumab + Tremelimumab + CT vs CT: PFS and OS

PFS

	D+T+CT	CT
Events, n/N (%)	238/338 (70.4)	258/337 (76.6)
mPFS, months (95% CI)	**6.2** (5.0–6.5)	**4.8** (4.6–5.8)
HR (95% CI)	**0.72** (0.60–0.86)	
p-value	0.00031	

26.6%

13.1%

Probability of PFS

Time from randomization (months)

No. at risk
D+T+CT	338	243	161	94	56	32	13	5	0
CT	337	219	121	43	23	12	3	2	0

- Median follow-up in censored patients at DCO: 10.3 months (range 0–23.1)

OS

	D+T+CT	CT
Events, n/N (%)	251/338 (74.3)	285/337 (84.6)
mOS, months (95% CI)	**14.0** (11.7–16.1)	**11.7** (10.5–13.1)
HR (95% CI)	**0.77** (0.65–0.92)	
p-value	0.00304	

32.9%

22.1%

Probability of OS

Time from randomization (months)

No. at risk
D+T+CT	338	298	256	217	183	159	137	120	109	95	88	64	41	20	9	0	0
CT	337	284	236	204	160	132	111	91	72	62	52	38	21	13	6	0	0

- Median follow-up in censored patients at DCO: 34.9 months (range 0–44.5)

DCO PFS FA: Jul 24, 2019; DCO OS FA: Mar 12, 2021

Co-mutational status (STK11, KEAP, TP53) and PD-L1 expression in *KRAS* mutant non-small cell lung cancer (NSCLC)

- Molecular profiles of 27748 NSCLC tumors were tested with next-generation sequencing (Caris Life Sciences, Phoenix, AZ) and classified by *KRAS* mt.
- PD-L1 IHC (22C3) was reported as TPS.
- Co-occurring genomic alterations, tumor mutational burden (TMB) and PD-L1 IHC (22C3, TPS score) were analyzed by *KRAS* mt type.
- Real-world post-immunotherapy (IO) overall survival (OS) was obtained from insurance claims and calculated from start of an immune check-point inhibitor (with or without chemotherapy) to the last day of follow-up.
- Prognosis was evaluated by rwOS calculated from tissue collection to last contact
- Molecular groups including K-only, KP, KL, KK and KKL were defined based on distinct mutational status of four genes as described below.

End point: Median rwOS (Tissue collection to Last Contact)		
	mrwOS (m)	95% CI
K-only	23.1	20.9-25.3
KP	17.7	16.2-19.35
KL	19.1	16.6-21.2
KK	9.7	7.4-14.2
KKL	8.0	6.6-9.0

- We report a large real-world dataset evaluating outcomes with check-point inhibitors in NSCLCs with *KRAS* and specific co-mts. Across the subgroups, KKL (KRAS mt/STK-11 mt/KEAP-1 mt) demonstrated universally poor outcomes in all *KRAS* subtypes; irrespective of PD-L1 expression.

Molecular Groups	Gene mutations			
	KRAS	STK11	TP53	KEAP1
K-only	MT	WT	WT	WT
KP	MT	WT	MT	WT
KL	MT	MT	WT	WT
KK	MT	WT	WT	MT
KKL	MT	MT	WT	MT

Table 1: Molecular sub-groups

PFS and Response in *STK11*m Subgroup

PFS

	T+D+CT	D+CT	CT
Events, n/N	22/31	27/34	17/22
mPFS, mo (95% CI)	**6.4** (4.7–13.8)	**2.9** (1.4–4.7)	**4.6** (2.9–6.4)
HR* (95% CI)	**0.47** (0.23–0.93)	**1.02** (0.55–1.93)	–

No. at risk

T+D+CT	31	23	16	13	7	3	3	1	0
D+CT	34	17	10	7	5	2	1	0	0
CT	22	14	7	1	0	0	0	0	0

New lesion BOR: ● PD ● SD ● PR ● CR

T+D+CT
ORR 45.2% (27.3–64.0)
mDoR 13.6 mo (5.1–NE)
n=28†

D+CT
ORR 29.4% (15.1–47.5)
mDoR 12.7 mo (1.6–NE)
n=29†

CT
ORR 27.3% (10.7–50.2)
mDoR 3.3 mo (2.8–NE)
n=22†

Schedule of treatment

BOR, best objective response; CR, complete response; mDoR; median duration of response; mPFS, median PFS; NE, not estimable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease

*HR <1 favours D (± T) + CT versus CT (unstratified analysis); †Patients who have both a baseline and post-baseline target lesion measurement Assessed by BICR among mutation-evaluable patients with NSQ tumour histology; confirmed objective responses are shown; DCO, 24 Jul 2019

First Line Lung Cancer Therapy with no actionable genes

Chemotherapy/IO Combinations

- Carboplatin/Pemetrexed/Pembrolizumab [Keynote 189]
- Carboplatin/Paclitaxel/Bevacizumab/Atezolizumab [IMPOWER 150]
- Carboplatin/Paclitaxel or nab-paclitaxel/Pembrolizumab [Keynote 407]
- Cemiplimab/Chemotherapy [Empower Lung-3]
- Durvalumab + Tremelimumab/Chemotherapy [Poseidon 3]

IO single Agent (PDL1>50%)

- Pembrolizumab [Keynote 024 and 042]
- Atezolizumab [IMPOWER 110]
- Cemiplimab [Empower Lung-1]

Immunotherapy combinations:

- Ipilimumab and Nivolumab [Checkmate 227]
- Ipilimumab and Nivolumab plus 2 cycles of chemotherapy [Checkmate 9LA]

ORR slightly in favor of combination chemo+IO

	KN 24 (TPS > 50%)	KN 42 (TPS > 50%)	IMPW 10 TC3/IC3 (>50% and >10%)	KN 407 (TPS > 50%)	KN 189 (TPS > 50%)
ORR	45%	39.5%	30.7%	60.3%	61.4%
DOR	Nr (1.8-20.6 m)	20.2 m	Nr (1.8-29.3m)	7.7 m (all patients)	11.2 m (all patients)

Reck M, NEJM 2016, Mok T et al, Lancet 2019, Paz Ares, NEJM 2018, Ghandi, NEJM 2018

Adverse Events more prevalent with Chemo/IO

	KN-42		KN-24		KN-189		KN-407	
	Pembro	CT	Pembro	CT	Pembro + CT	CT	Pembro + CT	CT
All TRAE (%)	62.7%	89.9%	76.6%	90.0%	99.8%	99.0%	98.2%	97.9%
Grade 3-5 TRAE (%)	17.8%	41%	31.2%	53.3%	67.2%	65.0%	69.8%	68.2%
Discontinuation rate (any) (%)	9%	9.4%	13.6%	10.7%	27.7%	14.9%	23.4%	11.8%
Led to death	0.2%	0%	1.3%	2.0%	6.7%	5.9%	8.3%	6.4%

Reck M, NEJM 2016, Mok T et al, Lancet 2019, Paz Ares, NEJM 2018, Ghandi, NEJM 2018

Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA Pooled Analysis

Oladimeji Akinboro[1], Jonathon Vallejo[1], Erica Nakajima[1], Yi Ren[1], Pallavi Mishra-Kalyani[1], Erin Larkins[1], Paz Vellanki[1], Nicole Drezner[1], Mathieu Luckson[1], Shenghui Tang[1], Martha Donoghue[1,2], Richard Pazdur[1,2], Julia A. Beaver[1,2], Harpreet Singh[1,2]

[1]Center for Drug Evaluation and Research, U.S. Food and Drug Administration

[2]Oncology Center of Excellence, U.S. Food and Drug Administration

Oladimeji Akinboro, MD, MPH

2022 ASCO®
ANNUAL MEETING

#ASCO22

PRESENTED BY:
Oladimeji Akinboro, MD, MPH

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

ASCO®
AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Clinical trials of first-line Chemo-IO and IO regimens included in FDA pooled analysis

Chemo-IO Trials		IO-only Trials	
Trial	**Investigational Regimen**	**Trial**	**Investigational Regimen**
KEYNOTE-021*	**Pembrolizumab** + Chemo**	CheckMate 026	**Nivolumab** **
KEYNOTE-189	**Pembrolizumab** + Chemo**	KEYNOTE-024	**Pembrolizumab** **
KEYNOTE-407	**Pembrolizumab** + Chemo**	KEYNOTE-042	**Pembrolizumab** **
IMpower150	**Atezolizumab** + Bevacizumab + Chemo***	IMpower110	**Atezolizumab** **
IMpower130	**Atezolizumab** + Chemo**	CheckMate 227	**Nivolumab** + **Ipilimumab** **
CheckMate-9LA	**Nivolumab** + **Ipilimumab** + Chemo**	EMPOWER-Lung 1	**Cemiplimab** **

Abbreviations: Chemo-IO=platinum-based doublet chemotherapy immunotherapy; IO=immunotherapy.
* Cohort G
** Control arms: Platinum-based doublet chemotherapy
*** Control arm in IMpower150: Bevacizumab plus platinum-based doublet chemotherapy

Exploratory OS, PFS, and ORR: NSCLC PD-L1 ≥50%

	Chemo-IO (N=455)		IO-alone (N=1,298)
OS			
Median, months (95% CI)	25.0 (19.0, NE)		20.9 (18.5, 23.1)
HR (95% CI)		0.82 (0.62, 1.08)	
PFS			
Median, months (95% CI)	9.6 (8.4, 11.1)		7.1 (6.3, 8.3)
HR (95% CI)		0.69 (0.55, 0.87)	
ORR			
% (95% CI)	61 (56, 66)		43 (41, 46)
Odds ratio		1.2 (1.1, 1.3)	

Abbreviations: Chemo-IO=platinum-based doublet chemotherapy plus immunotherapy; CI=confidence interval; HR-hazards ratio; IO=immunotherapy; N=number; NSCLC=non-small-cell lung cancer; NE=not estimable; ORR=objective response rate; OS=overall survival; PD-L1=programmed death ligand-1; PFS=progression-free survival.

PRESENTED BY:
Oladimeji Akinboro, MD, MPH

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Kaplan-Meier plots for PD-L1–high (≥50%) patients: the survival outcomes for patients who are (A) PROphet-positive and (B) PROphet-negative, treated with either an ICI-chemotherapy combination or ICI monotherapy.

Christopoulous et al. JCO Precision Oncology. Volume 8. https://doi.org/10.1200/PO.23.00555

Figure 4. Overcoming resistance to immunotherapy. **A,** Increase tumor visibility. **B,** Enhance T-cell infiltration. **C,** Remove TME barriers. **D,** Enhance T-cell/NK-cell function. **E,** Unfavorable genomics/epigenetics. **F,** Adapt to the host.

Aldea M, et al. *Cancer Discov*. 2021;11(4):874-899.

CLINICAL CANCER RESEARCH | CLINICAL TRIALS: IMMUNOTHERAPY

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Matthew D. Hellmann[1], Pasi A. Jänne[2], Mateusz Opyrchal[3], Navid Hafez[4], Luis E. Raez[5], Dmitry I. Gabrilovich[6], Fang Wang[6], Jane B. Trepel[7], Min-Jung Lee[7], Akira Yuno[7], Sunmin Lee[7], Susan Brouwer[8], Serap Sankoh[8], Lei Wang[8], David Tamang[8], Emmett V. Schmidt[9], Michael L. Meyers[8], Suresh S. Ramalingam[10], Elaine Shum[11], and Peter Ordentlich[8]

- Entinostat (ENT) is an oral class I-selective histone deacetylase inhibitor
- ENT leads to downregulation of immunosuppressive cell types in the tumor microenvironment
- Synergy with anti-PD1 inhibition in preclinical models
- Promising activity shown in combination with pembrolizumab in patients with melanoma and lung cancer

- **Objective response rate with ENT + PEMBRO was 10% (7 of 72, 95% CI: 4-19%)**
  - **Median duration of response was 5.3 months**
  - **An additional 50% of patients achieved disease stabilization**
- **Median progression-free survival = 2.8 months (95% CI: 2.1-4.1)**

Helllman M (Raez L) Clin Can Research 2021 Feb 15;27(4):1019-1028.

Targeting angiogenesis to overcome ICI resistance

Fukumura et al., *Nat Rev Clin Oncol* 2018; Chen et al., *Biomarker Res* 2021

Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy—Lung-MAP non-matched sub-study S1800A

Karen L. Reckamp, M.D.[1], Mary W. Redman, PhD[2], Konstantin H. Dragnev, M.D.[3], Liza Villaruz, M.D.[4], Bryan Faller, MD[5]; Tareq Al Baghdadi, MD[6], Susan Hines, MD[7], Lu Qian, M.S.[2], Katherine Minichiello, M.S.[2], David R. Gandara, M.D.[8], Karen Kelly, MD[8], Roy S. Herbst, M.D., Ph.D.[9]

[1]Cedars-Sinai Medical Center, Los Angeles, CA; [2]SWOG Statistics and Data Management Center & Fred Hutchinson Cancer Research Center, Seattle, WA; [3]Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon, NH/Alliance for Clinical Trials in Cancer; [4]University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center; [5]Missouri Baptist Medical Center, St. Louis, MO/Heartland NCORP; [6]IHA Hematology Oncology Consultants-Ann Arbor/Michigan CRC NCORP; [7]Novant Health Cancer Institute - Mount Airy/Southeast Clinical Oncology Research Consortium NCORP); [8]UC Davis Comprehensive Cancer Center, Sacramento, CA; [9]Yale University, New Haven, CT

2022 ASCO® ANNUAL MEETING   #ASCO22

PRESENTED BY:
Karen L. Reckamp, MD, MS

LUNG-MAP

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

ASCO® AMERICAN SOCIETY OF CLINICAL ONCOLOGY   KNOWLEDGE CONQUERS CANCER

Overall survival

	N	Events	Median in months	80% Conf. Int
Ramucirumab+Pembrolizumab	69	45	14.5	(13.9-16.1)
Standard of Care (Inv. Choice)	67	51	11.6	(9.9-13.0)

HR(80% CI): 0.69 (0.51-0.92)
Standard log-rank p-value: 0.05
Weighted log-rank p-value: 0.15

- Median OS for RP 14.5 months v. SOC 11.6 months

- HR= 0.69; SLR p-value 0.05

Standard of care therapy received:
- Docetaxel + Ramucirumab (n = 45)
- Docetaxel (n = 3)
- Gemcitabine (n = 12)
- Pemetrexed (n = 1)
- No treatment (n = 6)

PRAGMATICA LUNG, Phase 3 trial ongoing........

NCT03971474

Stratified by 1) PD-L1 expression, 2) histology, 3) intent to receive ramucirumab in standard of care arm

Primary endpoint: OS

Secondary endpoints: RR, DCR, DoR, PFS, Toxicities

ARM A
Investigator's Choice Standard of Care
docetaxel + ramucirumab; docetaxel; gemcitabine; pemetrexed (nonSCC only)

Randomization

R (1:1)
N= 130

ARM B
Pembrolizumab
200 mg Q3W for up to 35 cycles
+
Ramucirumab
10 mg/kg Q3W

Key eligibility: 1) Previously received both PD-1 or PD-L1 inhibitor therapy and platinum-based doublet chemotherapy either sequentially or combined, with PD on at least 84 days after initiation of ICI and platinum-based doublet therapy; 2) ECOG 0-1; 3) all patients met eligibility to receive ramucirumab

Reckamp KL, et al. Presented at: ASCO;2022. Abstract 9004.

MRTX-500: Phase 2 Trial of Sitravatinib + Nivolumab in Patients With Nonsquamous Non–Small-Cell Lung Cancer Progressing on or After Prior Checkpoint Inhibitor Therapy

Ticiana A. Leal[1], David Berz[2], Igor I. Rybkin[3], Wade T. Iams[4], Debora S. Bruno[5], Collin M. Blakely[6], Alexander I. Spira[7], Manish R. Patel[8], David M. Waterhouse[9], Donald A. Richards[10], Anthony Pham[11], Robert Jotte[12], Edward B. Garon[13], David S. Hong[14], Ronald Shazer[15], Xiaohong Yan[15], Lisa Latven[15], Kai He[16]

Ticiana Leal. ESMO 2021.

TIGIT

- **TIGIT/CD155**:
- Directly inhibits T cells

- Triggers **IL-10** production, **IL-12** decrease from **APCs** = Indirectly inhibits T cells

- Enhances immunosuppressive **Treg** function

- Interaction with **gut microbiome**: Binds with Fusobacterium nucleatum = Inhibitory signaling

Mechanisms of TIGIT inhibition of T cells in TME

1: T/NK cell-intrinsic inhibition

2: Immunosuppressive DC

3: inhibition of CD226 signaling

4: Treg stability and suppression

5: Fap2-induced T/NK cell inhibition

Joe-Marc Chauvin, and Hassane M Zarour J Immunother Cancer 2020;8:e000957

Journal for ImmunoTherapy of Cancer

CITYSCAPE: Randomized Phase 2 Study of Tiragolumab + Atezolizumab in PD-L1+ Patients with NSCLC

1L Stage IV NSCLC

- *EGFR/ALK* wild-type
- Tumour PD-L1 TPS ≥1% by 22C3 IHC by local or central assay

N=135

R 1:1

Tiragolumab 600 mg IV Q3W + Atezolizumab 1200 mg IV Q3W

Placebo 600 mg IV Q3W + Atezolizumab 1200 mg IV Q3W

No crossover

PD or loss of clinical benefit

Stratification factors
- PD-L1 TPS (1–49% vs ≥50%)
- Histology (non-squamous vs squamous)
- Tobacco use (yes vs no)

Co-primary endpoints
- ORR and PFS

Key secondary endpoints
- Safety, DOR, OS

Exploratory endpoints
- Efficacy analysis by PD-L1 status, PROs

Primary analysis[1]
- Cut-off date of 30 June 2019
- Median follow-up of 5.9 months

Updated analysis
- Follow-up performed to assess safety and efficacy
- Cut-off date of 16 August 2021
- Median follow-up of 30.4 months

IHC, immunohistochemistry; PROs, patient-reported outcomes; TPS, tumor proportion score.

Rodriguez-Abreu D, et al. Presented at: ASCO;2020.

Investigator-Assessed PFS: PD-L1 Subgroups

PD-L1 TPS ≥50% (n=58)

	Events n (%)	Median PFS, months (95% CI)	PFS HR (95% CI)	ORR, %	Median DOR, months (95% CI)
Tira + atezo	21 (72.4)	16.6 (5.5–22.3)	0.29* (0.15–0.53)	69.0	15.7 (9.1–NE)
Placebo + atezo	28 (96.6)	4.1 (2.1–6.8)		24.1	8.2 (5.6–10.4)

12-month rate: 51.0%
12-month rate: 21.8%

No. at risk												
T + A	29	26	19	17	14	13	11	9	8	8	7	NE
P + A	29	17	9	7	6	2	1	1	NE	NE	NE	NE

PD-L1 TPS 1–49% (n=77)

	Events n (%)	Median PFS, months (95% CI)	PFS HR (95% CI)	ORR, %	Median DOR, months (95% CI)
Tira + atezo	36 (94.7)	4.0 (1.6–5.6)	1.07* (0.67–1.71)	15.8	17.8 (8.3–24.2)
Placebo + atezo	36 (92.3)	3.6 (1.4–5.5)		17.9	18.8 (15.9–22.8)

12-month rate: 24.9%
12-month rate: 20.5%

No. at risk												
T + A	38	22	12	12	9	6	5	3	3	1	1	1
P + A	39	21	12	8	8	8	8	5	4	3	2	2

Rodriguez-Abreu D, et al. Presented at: ASCO;2020.

*Unstratified.
Updated analysis data cut-off: 16 August 2021 (median follow-up: 30.4 months)
PD-L1 status determined by 22c3 IHC assay.

ARC-7: Randomized, Open-label, Phase 2 Study in First-Line, Metastatic, PD-L1-High NSCLC

Stage IV NSCLC

Key eligibility:
- Treatment-naïve for metastatic disease
- PD-L1 ≥50%, locally assessed by SP263[1] or 22C3[2]
- EGFR/ALK wild-type

N = 150

R
1:1:1

Strat. Factors:
ECOG 0 vs 1
Male vs Female

Arm 1

Zim (Z)*
360 mg IV Q3W

Arm 2

Dom + Zim (DZ)
15 mg/kg IV Q3W + 360 mg IV Q3W

Arm 3

Etruma + Dom + Zim (EDZ)
150 mg PO QD + 15 mg/kg IV Q3W + 360 mg IV Q3W

Scanning interval: Q6W for 6mo, then Q9W for 6mo, then Q12W thereafter

Co-primary endpoints
Investigator-assessed
ORR & PFS per RECIST v1.1

Secondary endpoints
Duration of response, disease control rate, overall survival, safety, PK/ADA

*Participants randomized to Arm 1 had the option to crossover to separate, 2L EDZ cohort upon radiographically confirmed disease progression (PD)

ADA: anti-drug antibody, Dom: domvanalimab, Etruma: etrumadenant, ORR: objective response rate, PFS: progression-free survival, PK: pharmacokinetics; R: randomized; Zim: zimberelimab; Q3W: every three weeks
[1]Ventana SP263 assay; [2]PharmDx 22C3 assay

PRESENTED BY: Melissa Johnson, MD, Director Lung Cancer Research
Sarah Cannon Research Institute at Tennessee Oncology
@MLJohnsonMD2

2023 ASCO ANNUAL MEETING   #ASCO23

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Progression-Free Survival (mITT)
Zim Monotherapy vs. Dom + Zim Doublet

	Median, mos [95% CI]	Events (%)	HR vs. Z [95% CI]
Z	5.4 [2.7, 9.7]	32 (64%)	-
DZ	9.3 [4.1, NE]	27 (54%)	0.67 [0.40, 1.13]

6-mo PFS DZ: 58%

12-mo PFS DZ: 41%

6-mo PFS Z: 45%

12-mo PFS Z: 25%

At Risk:
Z =	50	30	27	16	12	8	7	7	6	5	4	3	2	1	1
DZ =	50	39	32	23	19	17	14	11	9	5	4	1	1	1	1

CI: confidence interval; HR: hazard ratio; Mos: months; NE: not evaluable

Addition of dom to zim resulted in 33% reduction in risk of progression or death as compared to zim alone

2023 ASCO ANNUAL MEETING   #ASCO23

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Conclusions

- In an updated analysis of ARC-7, with longer median follow-up of 18.5 months, dom-containing arms continued to demonstrate clinically meaningful improvement in ORR and PFS as compared to zim monotherapy. Specifically, TIGIT combinations resulted in:
  - Greater ORR, Δ: +10 to 14%, compared to zim alone
  - Approximately 30% reduction in risk of progression or death compared to zim alone
- Clinical activity and safety of zim performed as expected with agents in the anti-PD-1 class
- Dom + zim combinations with or without etruma were generally well-tolerated with similar, manageable safety profiles across all arms
  - Rates of infusion-related reactions were low across dom-containing arms (4 – 12%), as intended with the Fc-silent design of dom
- The data presented support the ongoing phase 3 studies with domvanalimab: ARC-10 (NCT04736173), STAR-121 (NCT05502237), STAR-221 (NCT05568095) and PACIFIC-8 (NCT05211895)

Current trials in Stage IV NSCLC targeting TIGIT

	VELOCITY-Lung	STAR-121	ARC-7	KEYVIBE-007	KEYVIBE-003	SKYSCRAPER-01	CITYSCAPE
	NCT05633667	NCT05502237	NCT04262856	NCT05226598	NCT04738487	NCT04294810	NCT03563716
Anti-TIGIT	Domvanalimab (DOM)	Domvanalimab (DOM)	Domvanalimab	Vibostolimab*	Vibostolimab*	Tiragolumab	Tiragolumab
Immunotherapy	Zimberelimab (ZIM)	Zimberelimab (ZIM)	Zimberelimab (ZIM)	Pembrolizumab*	Pembrolizumab*	Atezolizumab	Atezolizumab
Additional Tx	Sacituzumab govitecan (SG)/ Etrumadenant (ETRUMA)	Chemotherapy	Etrumadenant (ETRUMA)	Chemotherapy	n/a	n/a	n/a
Control Arm	SOC	Pembrolizumab + CT	Zimberelimab	Pembrolizumab + CT	Pembrolizumab	Placebo + Atezolizumab	Placebo + Atezolizumab
Line of Therapy	1 L	1L	1L	1L	1L	1L	1L
Histology	NSQ	NSQ/SQ	NSQ/SQ	NSQ/SQ	NSQ/SQ	NSQ/SQ	NSQ/SQ
Patient Population	Non-AGA	No EGFR/ALK	PD-L1 >50% No EGFR/ALK	Non-AGA	No EGFR/ALK/ROS1 PD-L1 $\geq$1%	Non-AGA PD-L1 $\geq$50%	CT Naïve
Start Date	Not Yet Recruiting	October 2022	May 2020	March 2022	April 2021	March 2020	August 2018
Estimated Completion Date	January 2027	December 2027	February 2024	September 2025	April 2026	February 2025	June 2019
Primary Outcome	ORR	PFS/OS	ORR/PFS	PFS/OS	OS	PFS/OS	ORR: 31.3% PFS: 5.4 months
Trial Type	Phase II	Phase III	Phase II	Phase III	Phase III	Phase III	Phase II

*Coformulation (MK-7684A)

LUNAR Phase 3 Study Design

Objective: To evaluate safety and efficacy of TTFields therapy with standard of care (SOC) compared to SOC alone in metastatic NSCLC progressing on or after platinum-based therapy

Key eligibility criteria
- ≥22 years of age
- Metastatic NSCLC
- Progression on/after platinum-based therapy
- ECOG PS 0–2

Baseline evaluation (incl. MRI)

N=276

Randomized (1:1)

Stratified by region, SOC treatment, and histology

TTFields therapy* and SOC (Investigator's choice ICI[†] or docetaxel)

Q6W follow-up until progression

SOC (Investigator's choice ICI[†] or docetaxel)

Q6W follow-up until progression

3 post-progression follow-up visits

Survival follow-up

**Data cut-off:** November 26, 2022
Study sites: 124 in 17 countries (North America, Europe, Asia)

*150 kHz; ≥18 h/day; [†]pembrolizumab, nivolumab, or atezolizumab.
ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer; Q6W, every 6 weeks; SOC, standard of care; TTFields, Tumor Treating Fields.

Overall Survival in the ITT Population

|	TTFields + SOC (n=137)	SOC (n=139)
Median OS (95% CI), months	13.2 (10.3–15.5)	9.9 (8.1–11.5)
1-year survival (95% CI)	53% (44–61)	42% (34–50)
3-year survival (95% CI)	18% (11–27)	7% (2–15)

HR (95% CI): 0.74 (0.56–0.98)
P=0.035

No. at Risk:

TTFields + SOC	137	100	62	36	22	16	11	9	5	3
SOC	139	96	54	32	16	7	3	0	0	0

CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival; SOC, standard of care; TTFields, Tumor Treating Fields.

Median (range) follow-up: 10.0 (0.03–58.7) months

Overall Survival in ICI-Treated Patients

	TTFields + ICI (n=66)	ICI (n=68)
Median OS (95% CI), months	18.5 (10.6–30.3)	10.8 (8.2–18.4)
1-year survival (95% CI)	60% (47–71)	46% (33–57)
3-year survival (95% CI)	27% (15–42)	9% (3–21)

HR (95% CI): 0.63 (0.41–0.96)
P=0.03

No. at Risk:

TTFields + ICI	66	50	35	24	16	12	8	6	2	1
ICI	68	49	29	21	11	6	3	0	0	0

CI, confidence interval; HR, hazard ratio; ICI, immune checkpoint inhibitor; OS, overall survival; TTFields, Tumor Treating Fields.

Progression-free Survival in the ITT Population

	TTFields + SOC (n=137)	SOC (n=139)
Median PFS (95% CI), months	4.8 (4.1–5.7)	4.1 (3.1–4.6)

HR (95% CI): 0.85 (0.67–1.11)
P=0.23

No. at risk:

TTFields + SOC	137	44	17	9
SOC	139	40	21	9

PFS was defined as the time from date of randomization until date of disease progression, or death by any cause.
CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; PFS, progression-free survival; SOC, standard of care; TTFields, Tumor Treating Fields.

Thanks

@LuisRaezMD